Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 3.68 USD 4.55% Market Closed
Market Cap: 208.9m USD

Intrinsic Value

DSGN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one DSGN stock under the Base Case scenario is 4.32 USD. Compared to the current market price of 3.68 USD, Design Therapeutics Inc is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DSGN Intrinsic Value
4.32 USD
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare DSGN to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about DSGN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Design Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Design Therapeutics Inc

Current Assets 234m
Cash & Short-Term Investments 229.7m
Receivables 1.4m
Other Current Assets 2.9m
Non-Current Assets 3m
PP&E 3.4m
Other Non-Current Assets -400k
Efficiency

Free Cash Flow Analysis
Design Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Design Therapeutics Inc

Revenue
0 USD
Operating Expenses
-68m USD
Operating Income
-68m USD
Other Expenses
11m USD
Net Income
-57m USD
Fundamental Scores

DSGN Profitability Score
Profitability Due Diligence

Design Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
28/100
Profitability
Score

Design Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

DSGN Solvency Score
Solvency Due Diligence

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DSGN Price Targets Summary
Design Therapeutics Inc

Wall Street analysts forecast DSGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DSGN is 7.48 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

Lowest
Price Target
5.05 USD
37% Upside
Average
Price Target
7.48 USD
103% Upside
Highest
Price Target
12.6 USD
242% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Design Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DSGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

DSGN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one DSGN stock?

The intrinsic value of one DSGN stock under the Base Case scenario is 4.32 USD.

Is DSGN stock undervalued or overvalued?

Compared to the current market price of 3.68 USD, Design Therapeutics Inc is Undervalued by 15%.

Back to Top